Locally Advanced or Metastatic Pancreatic Cancer
Conditions
Keywords
Pancreatic Cancer
Brief summary
Objectives * Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib * Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib
Interventions
DRUGFG-3019
3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
Sponsors
Kyntra Bio
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written informed consent 2. Males and females aged ≥18 years old 3. Histologically or cytologically confirmed adenocarcinoma of the pancreas 4. Locally advanced (Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas 5. Spiral CT scan demonstrating at least one pancreatic adenocarcinoma measurable lesion according to RECIST criteria and PET scan showing metabolically active lesion (for the last six subjects in the 15 mg/kg and the subjects in the 25 mg/kg FG-3019 dose cohorts only) 6. Women of childbearing potential and men must use effective contraception during and for at least 90 days following study participation. Women of childbearing potential must have a negative Screening serum pregnancy test. 7. ECOG performance status score of 0-1 8. Life expectancy \>12 weeks 9. Ability to adhere to the study visit schedule and understand and comply with all protocol requirements and instructions from study staff
Exclusion criteria
1. Absolute neutrophil count (ANC) \<500 cells/mm3 2. Hemoglobin \<10.0 g/dL 3. Platelet count \<100,000 cells/mm3 4. Bilirubin \>2.0 x upper limit of normal (ULN) 5. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2.5 x ULN, or \>3.5 x ULN if liver metastases are present 6. If the subject is diabetic, HbA1c \>10% 7. Current pregnancy or breast feeding due to recent pregnancy 8. History of another malignancy in the past 2 years with the exception of basal cell or squamous cell carcinoma of the skin 9. Previous chemotherapy with gemcitabine 10. Previous systemic antineoplastic agent (other than adjuvant 5-fluorouracil as radio-sensitizer) 11. Adjuvant 5-fluorouracil within 28 days prior to Day 1 12. Major surgery within 28 days prior to Day 1 (stent placement is allowed) 13. Radiation therapy within 28 days prior to Day 1 14. Clinical evidence or any history of brain metastasis 15. Uncontrolled hypertension (systolic blood pressure \[SBP\] \>180 mmHg or diastolic blood pressure \[DBP\] \>105 mmHg) 16. New York Heart Association Class III or IV congestive heart failure 17. History of allergic or anaphylactic reaction to human, humanized, or chimeric monoclonal antibodies 18. Current clinical or laboratory evidence of active infection requiring antibiotic or antiviral therapy 19. Active major gastrointestinal bleeding 20. Full-dose heparin therapy within 28 days prior to Day 1 21. Participation in studies of investigational products within 42 days prior to Day 1 22. Clinically significant and uncontrolled medical condition considered a high risk for participation in an investigational study or a likelihood that the subject will be unable to comply with protocol requirements and complete the trial (e.g., emphysema requiring supplemental oxygen, poorly controlled arrhythmia, psychiatric illness, Alzheimer's disease) 23. Current abuse of alcohol or drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib | Through the end of the study |
Secondary
| Measure | Time frame |
|---|---|
| FG-3019 PK parameters | Through the end of the study |
| Time to Progression (TTP) | Through the end of the study |
| 6-month, 12-month and overall median survival rates | Through the end of the study |
| Maximal tumor response as determined by RECIST criteria | Through the end of the study |
Countries
United States
Outcome results
None listed